TY - JOUR
T1 - Photoimmunotheranostic agents for triple-negative breast cancer diagnosis and therapy that can be activated on demand
AU - Amoury, Manal
AU - Bauerschlag, Dirk
AU - Zeppernick, Felix
AU - Felbert, Verena von
AU - Berges, Nina
AU - Fiore, Stefano Di
AU - Mintert, Isabell
AU - Bleilevens, Andreas
AU - Maass, Nicolai
AU - Bräutigam, Karen
AU - Meinhold-Heerlein, Ivo
AU - Stickeler, Elmar
AU - Barth, Stefan
AU - Fischer, Rainer
AU - Hussain, Ahmad Fawzi
PY - 2016
Y1 - 2016
N2 - Triple-negative breast cancer (TNBC) is a heterogeneous disease in which the tumors do not express estrogen receptor (ER), progesterone receptor (PgR) or human epidermal growth factor receptor 2 (HER2). Classical receptor-targeted therapies such as tamoxifen or trastuzumab are therefore unsuitable and combinations of surgery, chemotherapy and/or radiotherapy are required. Photoimmunotheranostics is a minimally invasive approach in which antibodies deliver nontoxic photosensitizers that emit light to facilitate diagnosis and produce cytotoxic reactive oxygen species to induce apoptosis and/or necrosis in cancer cells. We developed a panel of photoimmunotheranostic agents against three TNBC-associated cell surface antigens. Antibodies against epidermal growth factor receptor (EGFR), epithelial cell adhesion molecule (EpCAM) and chondroitin sulfate proteoglycan 4 (CSPG4) were conjugated to the highly potent near-infrared imaging agent/photosensitizer IRDye®700DX phthalocyanine using SNAP-tag technology achieving clear imaging in both breast cancer cell lines and human biopsies and highly potent phototherapeutic activity with IC50 values of 62-165 nM against five different cell lines expressing different levels of EGFR, EpCAM and CSPG4. A combination of all three reagents increased the therapeutic activity against TNBC cells by up to 40%.
AB - Triple-negative breast cancer (TNBC) is a heterogeneous disease in which the tumors do not express estrogen receptor (ER), progesterone receptor (PgR) or human epidermal growth factor receptor 2 (HER2). Classical receptor-targeted therapies such as tamoxifen or trastuzumab are therefore unsuitable and combinations of surgery, chemotherapy and/or radiotherapy are required. Photoimmunotheranostics is a minimally invasive approach in which antibodies deliver nontoxic photosensitizers that emit light to facilitate diagnosis and produce cytotoxic reactive oxygen species to induce apoptosis and/or necrosis in cancer cells. We developed a panel of photoimmunotheranostic agents against three TNBC-associated cell surface antigens. Antibodies against epidermal growth factor receptor (EGFR), epithelial cell adhesion molecule (EpCAM) and chondroitin sulfate proteoglycan 4 (CSPG4) were conjugated to the highly potent near-infrared imaging agent/photosensitizer IRDye®700DX phthalocyanine using SNAP-tag technology achieving clear imaging in both breast cancer cell lines and human biopsies and highly potent phototherapeutic activity with IC50 values of 62-165 nM against five different cell lines expressing different levels of EGFR, EpCAM and CSPG4. A combination of all three reagents increased the therapeutic activity against TNBC cells by up to 40%.
UR - http://www.scopus.com/inward/record.url?scp=84983488850&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.10705
DO - 10.18632/oncotarget.10705
M3 - Journal articles
C2 - 27448975
AN - SCOPUS:84983488850
SN - 1949-2553
VL - 7
SP - 54925
EP - 54936
JO - Oncotarget
JF - Oncotarget
IS - 34
ER -